phospho-CDKN1A/p21 (Thr57)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 5238R
英文名称phospho-CDKN1A/p21 (Thr57)
中文名称磷酸化辫21蛋白抗体
别 名CDKN1A/p21 (phospho Thr57); p21 (phospho T57); p21 (phospho Thr57); Activating Fragment 1; CAP20; Cation chloride cotransporter-interacting protein 1; CDK Interacting Protein 1; CDK-interacting protein 1; CDKI; CDKN 1; CDKN1; CDKN1A; CIP1; Cyclin Dependent Kinase Inhibitor 1A; Cyclin-dependent kinase inhibitor 1; Cyclin-dependent kinase inhibitor 1A (P21); Cyclin-dependent kinase inhibitor 1A (p21, Cip1); DNA Synthesis Inhibitor; MDA 6; MDA-6; MDA6; Melanoma Differentiation Associated Protein 6; Melanoma differentiation-associated protein 6; Melanoma differentiation-associated protein; p21; P21 protein; p21CIP1; p21WAF; PIC1; SDI1; SLC12A9; WAF1; Wildtype p53 Activating Fragment 1; Wildtype p53-activated fragment 1; CDN1A_HUMAN.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 **学 信号转导 细胞周期蛋白
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-CDKN1A/p21 (Thr57)抗体交叉反应 Human, Mouse, Rat,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量18kDa
细胞定位细胞核 细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human CDKN1A around the phosphorylation site of Thr57 [TE(p-T)PL]:TE(p-T)PL
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-CDKN1A/p21 (Thr57)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Two alternatively spliced variants, which encode an identical protein, have been reported.
Subcellular Location:
Cytoplasmic and Nuclear.
Tissue Specificity:
Expressed in spleen, liver and lung. Not detected in kidney, colon, stomach or brain.
Post-translational modifications:
Phosphorylation of Thr-145 by Akt or of Ser-146 by PKC impairs binding to PCNA. Phosphorylation at Ser-114 by GSK3-beta enhances ubiquitination by the DCX(DTL) complex. Phosphorylation of Thr-145 by PIM2 enhances CDKN1A stability and inhibits cell proliferation. Phosphorylation of Thr-145 by PIM1 results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability.
Ubiquitinated by MKRN1; leading to polyubiquitination and 26S proteasome-dependent degradation. Ubiquitinated by the DCX(DTL) complex, also named CRL4(CDT2) complex, leading to its degradation during S phase or following UV irradiation. Ubiquitination by the DCX(DTL) complex is essential to control replication licensing and is PCNA-dependent: interacts with PCNA via its PIP-box, while the presence of the containing the 'K+4' motif in the PIP box, recruit the DCX(DTL) complex, leading to its degradation.
Acetylation leads to protein stability. Acetylated in vitro on Lys-141, Lys-154, Lys-161 and Lys-163. Deacetylation by HDAC1 is prevented by competitive binding of C10orf90/FATS to HDAC1.
Similarity:
Belongs to the CDI family.
SWISS:
P38936
Gene ID:
1026
phospho-CDKN1A/p21 (Thr57)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-CDKN1A/p21 (Thr57)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 LCN8 附睾特异蛋白8抗体
合格 LCT 乳糖酶根皮苷水解酶1抗体
合格 合格 LCTL 乳糖酶样蛋白抗体
合格 LDLRAD2 低密度脂蛋白受体结构域蛋白2抗体
合格 LDLRAD3 低密度脂蛋白受体结构域蛋白3抗体
合格 Leishmania Major Surface Protease 利什曼原虫表面蛋白酶抗体
合格 LENG8 LENG8蛋白抗体
合格 LGALS9B 半乳糖凝集素9B抗体
合格 合格 LGI2 富含亮氨酸胶质瘤失活蛋白2抗体
合格 LHFPL1 脂肪瘤高迁移率融合蛋白样蛋白1抗体
合格 LHX8 LHX8蛋白抗体
合格 LIAS 硫辛酸合成酶抗体
合格 MYL2 心脏肌球蛋白轻链2抗体
合格 LILRA2/CD85h CD85h抗体
合格 Mitofilin 线粒体内膜蛋白抗体
合格 phospho-MCM2 (Ser27) 磷酸化MCM2蛋白抗体
合格 Inhibin Beta C 抑制素βC抗体
合格 LIM2 晶状体纤维膜内在蛋白抗体
合格 LIMCH1 LIMCH1蛋白抗体
合格 LIMD2 LIMD2蛋白抗体
合格 IL-11 白介素11抗体
合格 LIN9 LIN9蛋白抗体
合格 LINGO2 富含亮氨酸重复跨膜神经元2抗体
合格 LINS LINS蛋白抗体
合格 LIPC 肝脂酶抗体
合格 LIPM/Lipase M 脂肪水解酶LIPM抗体
合格 DLDD/Lipoamide Dehydrogenase 硫辛酰胺脱氢酶抗体
合格 LIPT2 硫辛酰连接酶2抗体
合格 Liprin alpha 2 酪氨酸磷酸酶受体相互作用蛋白Liprin α2抗体
合格 LIX1L Lix1样蛋白抗体
合格 合格 LMAN1L 凝集素甘露糖结合蛋白1样蛋白抗体
合格 LMBRD1 核输出信号相互作用蛋白抗体
合格 IL-16 白介素16抗体
合格 LMO7 LMO7蛋白抗体
合格 LMOD1 甲状腺相关眼病自身抗原抗体
合格 LMOD2 平滑肌蛋白LMOD2抗体